News

The results are being presented today in an oral session at the 9th European Breast Cancer Conference (EBCC) in Glasgow, Scotland at 9:45 AM local time. The ENCHANT-1

The acquisition adds to the comprehensive biotechnology services that AIBioTech currently provides to its clients by performing assessments that examine the effects of drugs, chemicals, biologics, and other

As part of the deal, Eisai will work with LSTM and UoL to discover and develop new drug candidates that efficiently eliminate the bacteria Wolbachia. LSTM is a

Andexanet alfa, which secured breakthrough therapy designation from the US FDA, is being developed as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated

As part of the deal, arGEN-X has licensed the firm’s POTELLIGENT CHOK1SV Cell Line Technology for use in the development of ARGX-110, a proprietary antibody in its pipeline.

The deal will allow Sanofi Pasteur to access the global PCV market of $4bn and the use of PCVs in all countries is recommended by the World Health

Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder. As part of the deal, Noven will grant Actavis a non-exclusive, royalty-bearing license to

A new distribution center in Singapore and the recent expansion of the company’s facilities in Billerica, Mass., will help PAREXEL more effectively manage clients’ global clinical trial supply

Under the deal, Falk Pharma will assume responsibility and all costs relating to the clinical development and marketing of RhuDex. In return, Medigene will get an upfront payment